港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长机构认为我国医美渗透率仍有较大提升空间

智通财经04-10

智通财经APP获悉，四环医药(00460)涨超5%，截止发稿涨5.77%，报0.55港元，成交额294万港元。业绩方面，公司此前发布截至2023年12月31日止年度业绩，总收益约为人民币18.605亿元;其中收入的变化，来自医美产品的收益为人民币4.499亿元，同比上升约200.3%，主要由于伴随国内疫情管控的全面放开以及消费需求的逐步回暖，集团旗下医美平台渼颜空间通过渠道库存的清理、与多家医美...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426101000?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-10 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426101000","market":"hk","top_or_hot":-1,"title":"港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，四环医药(00460)涨超5%，截止发稿涨5.77%，报0.55港元，成交额294万港元。业绩方面，公司此前发布截至2023年12月31日止年度业绩，总收益约为人民币18.605亿元;其中收入的变化，来自医美产品的收益为人民币4.499亿元，同比上升约200.3%，主要由于伴随国内疫情管控的全面放开以及消费需求的逐步回暖，集团旗下医美平台渼颜空间通过渠道库存的清理、与多家医美...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1100407.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 10:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1100407.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，四环医药(00460)涨超5%，截止发稿涨5.77%，报0.55港元，成交额294万港元。业绩方面，公司此前发布截至2023年12月31日止年度业绩，总收益约为人民币18.605亿元;其中收入的变化，来自医美产品的收益为人民币4.499亿元，同比上升约200.3%，主要由于伴随国内疫情管控的全面放开以及消费需求的逐步回暖，集团旗下医美平台渼颜空间通过渠道库存的清理、与多家医美...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1100407.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"XL二南方恒科","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1100407.html","article_id":"2426101000","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426101000","pubTimestamp":1712715302,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，四环医药涨超5%，截止发稿涨5.77%，报0.55港元，成交额294万港元。华泰证券表示，23年医美行业新品获批阶段性空窗期，叠加需求较弱，倒逼下游机构“以价换量”，同质化较强/成熟度较高/价格带透明的产品易陷入低价引流困境，预计24年新品获批数量相较23年增加，对于终端需求有提振作用。中长期来看，我国医美渗透率仍有较大提升空间。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"07226":"XL二南方恒科","BK1593":"医美概念股","BK1191":"制药","BK1600":"工业大麻","BK4588":"碎股","YINN":"三倍做多富时中国ETF-Direxion","00460":"四环医药","YANG":"三倍做空富时中国ETF-Direxion","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Hong Kong stocks changed Sihuan Pharmaceutical (00460) rose by more than 5% in 23 years. The company's medical beauty revenue has increased significantly. Institutions believe that there is still a lot of room for improvement in the penetration rate of medical beauty in my country","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1,"07226":1,"YANG":1,"YINN":1},"content_text":"智通财经APP获悉，四环医药(00460)涨超5%，截止发稿涨5.77%，报0.55港元，成交额294万港元。业绩方面，公司此前发布截至2023年12月31日止年度业绩，总收益约为人民币18.605亿元;其中收入的变化，来自医美产品的收益为人民币4.499亿元，同比上升约200.3%，主要由于伴随国内疫情管控的全面放开以及消费需求的逐步回暖，集团旗下医美平台渼颜空间通过渠道库存的清理、与多家医美机构实现战略合作以及大力推广营销战略3.0版本升级所取得阶段性的成功，成功实现了医美销售收入的大幅回升。华泰证券表示，23年医美行业新品获批阶段性空窗期，叠加需求较弱，倒逼下游机构“以价换量”，同质化较强/成熟度较高/价格带透明的产品易陷入低价引流困境，预计24年新品获批数量相较23年增加，对于终端需求有提振作用。中长期来看，我国医美渗透率仍有较大提升空间。监管加强有助行业高质量健康发展，看好行业内产品矩阵丰富/研发实力强劲/有齐全牌照的龙头公司。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426101000"}

港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间

精彩评论

港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长机构认为我国医美渗透率仍有较大提升空间